Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 16, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction event.
- Transaction Price: $52.26 per Ordinary Share ADR.
- Transaction Type: Increase in interest following dividend re-investment.
- Dividend Date: July 12, 2007.
Material Changes
The filing reports an increase in the interest of Dr. R G Greig in Ordinary Share ADRs. The specific quantity of shares acquired is listed as 46.58. This change resulted from the automatic re-investment of dividends paid to shareholders.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification of a director's transaction in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by Dr. R G Greig post-transaction to assess total exposure.
- Confirm the dividend amount per share paid on July 12, 2007, to validate the re-investment calculation.
- Check subsequent filings to ensure no other material transactions by directors occurred around this period.